Improving outcomes for aging and high-need populations KANSAS CITY, Mo., March 9, 2025 /PRNewswire/ -- Trualta, the leading learning and…
HONG KONG, March 9, 2025 /PRNewswire/ -- On March 5, during the 2025 Mobile World Congress (MWC25), the 5G UAV medical…
BOSTON, March 9, 2025 /PRNewswire/ -- OnPoint AR-AI, a group of privately held augmented reality (AR) technology companies pioneering AR…
LAS VEGAS, March 9, 2025 /PRNewswire/ -- C-suite leaders from Houston Methodist and Health Data Analytics Institute (HDAI) will be speaking at…
LOS ANGELES, March 08, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious…
Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also…
Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease…
ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and…
For Immediate Release – Not for Dissemination in the United States or through U.S. Newswire ServicesGreenville, South Carolina, March 07,…
TAMPA, Fla., March 07, 2025 (GLOBE NEWSWIRE) -- Better Choice Company Inc. (NYSE: BTTR) (“Better Choice” or the “Company”), a…